InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (8 ops.)
Insider track record
CEODisclosed buys
3
Disclosed sells
8
T+90 hit rate
25%
T+90 mean return
-26.7%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by Tesi Raymond Joseph, Chairman & CEO. Director active across 1 company, notably Inmune Bio, Inc.. In total, 15 filings have been logged. Split: 3 buys · 8 sells. Total volume traded: €1.6m. Activity tracked since 7 July 2021. The latest transaction was disclosed on 12 September 2024 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations15 total
15,380 shares@ US$6.3754.1% of flowCommon StockSEC:0001213900-24-079121:0
Ideal exit: 9 Jun 2025 (T+270)
18,028 shares@ US$8.326.6% of flowCommon StockSEC:0001213900-24-035722:0
Ideal exit: 14 Jan 2025 (T+270)
18,028 shares@ US$8.326.6% of flowCommon StockSEC:0001213900-24-035474:0
6,300 shares@ US$6.410.091% mcap2.1% of flowCommon StockSEC:0001213900-22-030210:0
Ideal exit: 20 Feb 2023 (T+270)
23,724 shares@ US$8.430.44% mcap10.2% of flowCommon StockSEC:0001213900-22-014507:0
3,626 shares@ US$20.000.15% mcap3.5% of flowCommon StockSEC:0001213900-21-056737:0
3,626 shares@ US$20.002.9% of flowCommon StockSEC:0001213900-21-056737
6,517 shares@ US$20.000.27% mcap6.3% of flowCommon StockSEC:0001213900-21-055422:0
6,517 shares@ US$20.005.2% of flowCommon StockSEC:0001213900-21-055422
23,616 shares@ US$20.000.99% mcap22.9% of flowCommon StockSEC:0001213900-21-054644:0
23,616 shares@ US$20.0019.0% of flowCommon StockSEC:0001213900-21-054644
30,000 shares@ US$3.914.6% of flowCommon StockSEC:0001213900-21-045373
30,000 shares@ US$3.910.24% mcap5.6% of flowCommon StockSEC:0001213900-21-045373:0
5,649 shares@ US$20.0184.5% of flowCommon StockSEC:0001213900-21-036352
5,649 shares@ US$20.0180.23% mcap5.4% of flowCommon StockSEC:0001213900-21-036352:0
15 of 15 declarations
About Tesi Raymond Joseph
Raymond Joseph Tesi is the Chairman & CEO of Inmune Bio, Inc. He leads the company with a focus on innovation in the biotechnology sector. Under his leadership, Inmune Bio is committed to developing therapeutic solutions to improve patient lives. His leadership is marked by a strategic approach and a strong results-oriented mindset.
